Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz; Amir Massarweh; Amos Stemmer; Salomon M. Stemmer

doi:10.1001/jamaoncol.2021.4390

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

Noa Eliakim-Raz, Amir Massarweh, Amos Stemmer, Salomon M. Stemmer^*

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

39 Scopus citations

Original language	English
Pages (from-to)	1716-1718
Number of pages	3
Journal	JAMA Oncology
Volume	7
Issue number	11
DOIs	https://doi.org/10.1001/jamaoncol.2021.4390
State	Published - Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamaoncol.2021.4390

Cite this

@article{c7ee3deab52f4ae5aba8b049b01df533,

title = "Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment",

author = "Noa Eliakim-Raz and Amir Massarweh and Amos Stemmer and Stemmer, {Salomon M.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.",

year = "2021",

month = nov,

doi = "10.1001/jamaoncol.2021.4390",

language = "אנגלית",

volume = "7",

pages = "1716--1718",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

AU - Eliakim-Raz, Noa

AU - Massarweh, Amir

AU - Stemmer, Amos

AU - Stemmer, Salomon M.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85113167630&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2021.4390

DO - 10.1001/jamaoncol.2021.4390

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 34379092

AN - SCOPUS:85113167630

SN - 2374-2437

VL - 7

SP - 1716

EP - 1718

JO - JAMA Oncology

JF - JAMA Oncology

IS - 11

ER -

Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

UN SDGs

Access to Document

Other files and links

Cite this